Clinical Trial Update: 68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating 68Ga-P16-093 PET imaging for diagnosing prostate cancer, in head-to-head comparison with mpMRI, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-P16-093 (P16-093 Ga-68 radiopharmaceutical)

Snippet

Sponsor: First Affiliated Hospital of Fujian Medical University | Conditions: Prostate Cancer (Adenocarcinoma) | Phase 1, Phase 2 | Status: RECRUITING